How does Zarxio work in your body? A plain-English explanation of Zarxio's mechanism of action, how fast it works, and what makes it different.
Zarxio (Filgrastim-sndz) works by telling your bone marrow to make more white blood cells called neutrophils. Neutrophils are your body's front-line defense against bacteria and other infections. When your neutrophil count drops too low — a condition called neutropenia — you become dangerously vulnerable to infections that a healthy immune system would easily fight off.
Zarxio is essentially a man-made version of a protein your body already produces naturally, called granulocyte colony-stimulating factor (G-CSF). By giving your body extra G-CSF through Zarxio injections, you supercharge your bone marrow's ability to produce neutrophils quickly.
Here is what happens after you inject Zarxio:
After a subcutaneous injection (under the skin), Zarxio is absorbed into your bloodstream. Peak blood levels are typically reached within 2 to 8 hours.
Once in your blood, Zarxio travels to your bone marrow — the spongy tissue inside your bones where blood cells are made. There, it binds to special receptors called G-CSF receptors on the surface of neutrophil precursor cells (immature cells that will become neutrophils).
When Zarxio locks onto these receptors, it sends a strong signal telling the precursor cells to:
Within hours to days, your bone marrow releases a wave of fresh neutrophils into your bloodstream. This raises your absolute neutrophil count (ANC) and restores your body's ability to fight infections.
With healthy neutrophil levels, your body can fight off bacteria, fungi, and other pathogens that could cause serious or life-threatening infections — especially important if your immune system has been weakened by chemotherapy or other conditions.
Chemotherapy drugs are designed to kill rapidly dividing cancer cells. The problem is that your bone marrow cells also divide rapidly — they are constantly making new blood cells to keep your immune system, oxygen delivery, and clotting systems running.
When chemotherapy damages these bone marrow cells, your body temporarily cannot produce enough neutrophils. This is called chemotherapy-induced neutropenia, and it usually happens 7 to 14 days after a chemotherapy treatment.
During this window, even a minor infection — a small cut, a common cold, bacteria from food — can become a medical emergency. Febrile neutropenia (low white blood cell count with fever) often requires hospitalization and IV antibiotics.
Zarxio shortens this danger window by pushing your bone marrow to recover faster. This means:
Zarxio starts working quickly, but the full effect builds over days:
The exact timeline depends on how low your counts are, what caused the neutropenia, and your individual response to the medication.
This rapid bone marrow stimulation is also why bone pain is the most common side effect of Zarxio — your marrow is working overtime, and that activity can cause aching in your bones, especially in the legs, hips, and lower back.
Zarxio is not the only G-CSF medication available. Here is how it compares:
Zarxio is a biosimilar to Neupogen (Filgrastim), meaning it is a near-identical copy of the original drug. Both contain Filgrastim and work the same way. The key difference is cost — Zarxio is significantly cheaper than brand-name Neupogen ($250-$450 vs. $500-$900 per syringe), which is why many insurance plans now prefer Zarxio.
Neulasta is a long-acting version of Filgrastim. A special molecule called PEG (polyethylene glycol) is attached to the Filgrastim, which makes it last much longer in your body. This means Neulasta only needs to be given once per chemotherapy cycle instead of daily.
The trade-off? Neulasta is more expensive per dose, though the convenience of one injection instead of many can be worth it for some patients. Your doctor will recommend whichever option is best for your situation.
Granix is another short-acting G-CSF product similar to Zarxio. Both require daily injections and work in the same way. The choice between them often comes down to insurance coverage, cost, and availability.
If you are curious about all the alternatives to Zarxio, we have a full guide that breaks down your options.
You may have heard Zarxio called a "biosimilar" and wondered what that means. Here is a simple explanation:
Traditional generic drugs are exact chemical copies of brand-name drugs. Biosimilars are slightly different — they are highly similar copies of biologic medications (drugs made from living cells). Because biologics are large, complex proteins, making an exact copy is not possible the way it is with a simple chemical molecule.
However, the FDA requires biosimilars to be shown to have:
Zarxio was the first biosimilar approved in the U.S. in 2015, paving the way for more affordable biologic treatments. For patients, the practical takeaway is simple: Zarxio works the same as Neupogen but costs less.
If you are having trouble finding Zarxio at your pharmacy, learn how to check availability online or search Medfinder to find it in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
